Arcadia Biosciences, Inc.
RKDA
$3.46
$0.20196.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -20.88% | 17.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -20.88% | 17.69% | |||
| Cost of Revenue | -38.94% | 63.76% | |||
| Gross Profit | 18.39% | -27.00% | |||
| SG&A Expenses | 17.87% | -16.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.33% | -0.87% | |||
| Operating Income | -20.74% | 12.87% | |||
| Income Before Tax | -240.86% | -163.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -241.54% | -163.89% | |||
| Earnings from Discontinued Operations | 93.72% | 45.50% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -152.11% | -251.93% | |||
| EBIT | -20.74% | 12.87% | |||
| EBITDA | -20.02% | 11.73% | |||
| EPS Basic | -151.90% | -251.83% | |||
| Normalized Basic EPS | -227.54% | 45.06% | |||
| EPS Diluted | -151.90% | -251.83% | |||
| Normalized Diluted EPS | -227.54% | 45.06% | |||
| Average Basic Shares Outstanding | 0.09% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||